1. Expert Insights on Psoriatic Arthritis From Washington, DC

2. Overview of PsA

3. Emerging Data: Tofacitinib

4. Methods: Tofacitinib Studies

5. Tofacitinib Efficacy (Mease): ACR20 Scores

6. Tofacitinib: ACR 50/70 Scores (Mease)

7. Tofacitinib Safety (Mease)

8. Tofacitinib Efficacy (Gladman): ACR 20 and ΔHAQ-DI

9. Ixekizumab: Emerging Data

10. Ixekizumab: Introduction

11. Ixekizumab: Introduction (cont)

12. Ixekizumab: Efficacy

13. Ixekizumab: Conclusions

14. Safety: Secukinumab

15. SEC: Introduction

16. SEC: Findings

17. SEC: AEs of Special Interest

18. SEC: Conclusions

19. IBD and SEC Use

20. SEC: Safety Findings

21. Incidence of IBD in PsA Studies: SEC Short-Term Period

22. SEC: Conclusions

23. Patient Education: IL-17 Inhibitors and IBD

24. Emerging Data: APR Early Onset

25. APR: Introduction

26. APR: Efficacy, Week 2

27. APR: Efficacy, Week 52

28. APR: Conclusions

29. Emerging Data: APR Long-Term Safety

30. APR Long-Term: Introduction

31. APR Safety: Week 0 to 52

32. APR: Serious AEs

33. Emerging Data: GUS

34. GUS: Introduction

35. GUS: Methods

36. GUS: ACR and PASI Scores at Week 24

37. GUS: Conclusions

38. Statin Benefits in PsA and AS

39. Statins in PsA and AS: Introduction

40. Statins in PsA and AS: Methods

41. Statins: Propensity Score Matched Analysis

42. Statins in PsA and AS: Conclusions

43. Patient Education: Statin Use

44. Concluding Remarks

45. Abbreviations

46. Abbreviations (cont)

47. Abbreviations (cont)